Bristol-Myers Squibb Co
(LTS:0R1F)
$
54.48
-1.095 (-1.97%)
Market Cap: 109.81 Bil
Enterprise Value: 153.11 Bil
PE Ratio: 0
PB Ratio: 6.41
GF Score: 84/100 Bristol-Myers Squibb Co at Wolfe Research Healthcare Conference Transcript
Nov 16, 2022 / 08:20PM GMT
Release Date Price:
$76.47
(+0.01%)
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research
Okay. Great. Well, thanks for joining us. I'm Tim Anderson, I'm the large cap biopharma analyst at Wolfe. And we're pleased to have with us Bristol-Myers Squibb for a fireside chat here. Chris Boerner, who's EVP and Chief Commercialization Officer at the company, joined Bristol in 2015, has held leadership positions in both the U.S. and ex-U.S. markets. And prior to Bristol, he was in various commercial roles at Seagen and Genentech and other places as well. So Chris, thanks for joining us.
Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
My pleasure. Thanks for the invitation.
Questions & Answers
Timothy Minton Anderson;Christopher S. Boerner
Wolfe Research, LLC - MD of Equity Research
I thought we'd start with maybe just some kind of 2023 outlook type of questions. So maybe you can just frame out what you see as pushes and pulls as we close out 2022.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot